Aspirin as a therapeutic agent in cardiovascular disease: A statement for healthcare professionals from the American heart association

Circulation

Volumn 96, Issue 8, 1997, Pages 2751-2753

  Hennekens, Charles H ^a   Dyken, Mark L ^a   Fuster, Valentin ^a  

^a NONE

Author keywords

AHA Medical Scientific Statements; Aspirin; Cardiovascular disease; Myocardial infarction; Prevention

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; TICLOPIDINE;

ACUTE HEART INFARCTION; BLEEDING; CARDIOVASCULAR DISEASE; HEART INFARCTION; HUMAN; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; STROKE; THROMBOCYTE AGGREGATION INHIBITION; TRANSIENT ISCHEMIC ATTACK;

EID: 0030773146     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.8.2751     Document Type: Review

References (20)

1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat N Biol. 1971;231:232-235.
2. Fuster V, Dyken ML, Vokonas PS, Hennekens C. Aspirin as a therapeutic agent in cardiovascular disease. Circulation. 1993;87: 659-675.
3. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349-360.
4. US Food and Drug Administration. Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use: proposed amendment to the tentative final monograph. Federal Register. June 13, 1996;61:30002.
5. Rogers WJ, Bowlby LJ, Chandra NC, French WJ, Gore JM, Lambrew CT, Rubison RM, Tiefenbrunn HJ, Weaver WD. Treatment of myocardial infarction in the United States (1990 to 1993): observations from the National Registry of Myocardial Infarction. Circulation. 1994;90:2103-2114.
6. Krumholz HM, Radford MJ, Ellerbeck EF, Hennen J, Meehan TP, Petrillo M, Wang Y, Kresowik TF, Jencks SF. Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries: patterns of use and outcomes. Circulation. 1995;92: 2841-2847.
7. Hennekens CH, Jonas MA, Buring JE. The benefits of aspirin in acute myocardial infarction: still a well-kept secret in the US. Arch Intern Med. 1994;154:37-39.
8. Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet treatment, I: prevention of vascular death, MI and stroke by prolonged antiplatelet therapy in different categories of patients. Br Med J. 1994;308:235-246.
9. Hennekens CH, Buring JE, Sandercock P, Collins R, Peto R. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation. 1989;80:749-756.
10. Hebert P, Fuster V, Hennekens CH. Antiplatelet and anticoagulant therapy in evolving MI and primary prevention. In: Fuster V, Verstraete M, eds. Thrombosis and Cardiovascular Disease. Philadelphia, Pa: WB Saunders; 1992;14:261-273.
11. Dyken ML, Barnett HJ, Easton JD, Fields WS, Fuster V, Hachinski V, Norris JW, Sherman DG. Low dose aspirin and stroke: 'It ain't necessarily so.' Stroke. 1992;23:1395-1399.
12. UK-TIA Study Group. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial interim results. Br Med J. 1988;296:316-320.
13. Antiplatelet Trialists Collaboration (Barnett H, Bousser M-G, Boysen G, Breddin K, Britton M, Cairns J, Canner P, Collins R, Cortellaro M, Daniels A, Deykin D, Elwood P, Elwin E-E, Eschwege E, Farrell B, Fields WS, Gent M, Gray R, Guiraud-Chaumeil B, Hennekens CH, Klimt C, Lewis HD, Loria Y, Lowenthal A, MacMahon C, Miller J, Peto R, Qizilbash N, Reuther R, Richards S, Rosen A, Sandercock P, Sorensen PS, Sweetnam D, Taylor W, Thibult N, van Gijn J, Vogel G, Warlow C, Yusuf S). Secondary prevention of vascular disease by prolonged antiplatelet therapy. Br Med J. 1988;296:320-331.
14. Hass WK, Easton JD, Adams HP Jr, Pryse-Phillips W, Molony BA, Anderson S, Kamm B. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med. 1989;321:501-507.
15. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
16. Aspirin for heart patients. FDA Drug Bull. 1985;15:34-36.
17. Aspirin for TIAs. FDA Drug Bull. 1980;10:2.
18. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129-135.
19. Buring JE, Hennekens CH, for the Women's Health Study Research Group. The Women's Health Study: summary of the study design. J Myocardial Ischemia. 1992;4:27-29.
20. US Preventive Services Task Force. Guide to Clinical Preventive Services. 2nd ed. Baltimore, Md: Williams & Wilkins; 1996.